Similar articles for PMID: 31311279

Year	Number of Results
1987	1
1988	1
1992	1
1996	1
1997	2
1999	2
2000	1
2001	2
2002	4
2004	3
2005	5
2006	3
2007	3
2008	2
2009	2
2010	4
2011	7
2012	5
2013	2
2014	5
2015	9
2016	6
2017	4
2018	3
2019	5
2020	5
2024	0

1

Challenges of the phase I drug development in non-small cell lung cancer.

Lin CC. Lin CC. Chin Clin Oncol. 2019 Jun;8(3):25. doi: 10.21037/cco.2019.06.03. Chin Clin Oncol. 2019. PMID: 31311279 Free article. Clinical Trial.

2

The changing landscape of phase I trials in oncology.

Wong KM, Capasso A, Eckhardt SG. Wong KM, et al. Nat Rev Clin Oncol. 2016 Feb;13(2):106-17. doi: 10.1038/nrclinonc.2015.194. Epub 2015 Nov 10. Nat Rev Clin Oncol. 2016. PMID: 26552953 Review.

3

Non-small cell lung cancer: meta-analysis of efficacy of chemotherapy.

McVie JG. McVie JG. Semin Oncol. 1996 Jun;23(3 Suppl 7):12-4. Semin Oncol. 1996. PMID: 8711495

4

Innovative Clinical Trials: The LUNG-MAP Study.

Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. Steuer CE, et al. Clin Pharmacol Ther. 2015 May;97(5):488-91. doi: 10.1002/cpt.88. Clin Pharmacol Ther. 2015. PMID: 25676724 Review.

5

Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.

Nixon NA, Khan OF, Imam H, Tang PA, Monzon J, Li H, Sun G, Ezeife D, Parimi S, Dowden S, Tam VC. Nixon NA, et al. Cancer. 2017 Dec 1;123(23):4672-4679. doi: 10.1002/cncr.30919. Epub 2017 Aug 17. Cancer. 2017. PMID: 28817175 Free article.

6

Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.

Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Veyrat-Follet C, et al. Clin Pharmacol Ther. 2000 Dec;68(6):677-87. doi: 10.1067/mcp.2000.111948. Clin Pharmacol Ther. 2000. PMID: 11180028

7

Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers.

Singh N, Bal A, Aggarwal AN, Das A, Behera D. Singh N, et al. Future Oncol. 2010 May;6(5):741-67. doi: 10.2217/fon.10.30. Future Oncol. 2010. PMID: 20465389 Review.

8

Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer.

Hamilton G. Hamilton G. Expert Opin Drug Metab Toxicol. 2013 Oct;9(10):1381-90. doi: 10.1517/17425255.2013.815724. Epub 2013 Jul 6. Expert Opin Drug Metab Toxicol. 2013. PMID: 23829480 Review.

9

Emerging drugs for EGFR-mutated non-small cell lung cancer.

Sukrithan V, Deng L, Barbaro A, Cheng H. Sukrithan V, et al. Expert Opin Emerg Drugs. 2019 Mar;24(1):5-16. doi: 10.1080/14728214.2018.1558203. Epub 2018 Dec 20. Expert Opin Emerg Drugs. 2019. PMID: 30570396 Review.

10

Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.

Gandara DR, Lara PN Jr, Mack P, Scagliotti G. Gandara DR, et al. Clin Lung Cancer. 2009 May;10(3):148-50. doi: 10.3816/CLC.2009.n.020. Clin Lung Cancer. 2009. PMID: 19443333 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

81 results

Results by year